CG Invites Co

CG Invites Co Inventory

The Inventory of CG Invites Co (083790.KQ) as of Oct 30, 2026 is 6.42 B KRW. In the previous year, Inventory was 9.18 B KRW — a change of -30.09% (lower).

Inventory

6.42 BKRW

YoY

-30.09%

Last updated:

Inventory of CG Invites Co is 2025 6.42 B KRW. Inventory of CG Invites Co was 2024 9.18 B KRW. It decreases by -30.09% lower compared to the previous year.

The CG Invites Co Inventory history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Inventory
Date
Inventory
Jan 1, 2018
449.05 M KRW
Jan 1, 2019
40.21 B KRW
Jan 1, 2020
10.01 B KRW
Jan 1, 2021
8.58 B KRW
Jan 1, 2022
5.68 B KRW
Jan 1, 2023
1.55 B KRW
Jan 1, 2024
9.18 B KRW
Jan 1, 2025
6.42 B KRW
The CG Invites Co Inventory history
YEARInventoryYoY
6.42 BKRW-30.09%
9.18 BKRW+490.48%
1.55 BKRW-72.61%
5.68 BKRW-33.81%
8.58 BKRW-14.31%
10.01 BKRW-75.10%
40.21 BKRW+8,853.88%
449.05 MKRW-13.21%
517.42 MKRW-87.05%
3.99 BKRW+214.53%
1.27 BKRW+1,083.17%
107.34 MKRW—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

CG Invites Co Stock analysis

What does CG Invites Co do? CrystalGenomics, Inc. generates revenue through its Finished Pharmaceuticals Manufacturing segment, which produces and sells finished pharmaceuticals. The Pharmaceutical R&D Division provides clinical trial analysis and technical services while also selling new drugs. The company also operates in the real estate leasing business under the segment structure. The Others segment manufactures and sells hot fats and other household items. Revenue streams are derived from pharmaceutical manufacturing, R&D services, real estate leasing, and household product sales. The primary buyers for finished pharmaceuticals include healthcare providers and distributors. Clinical trial analysis and new drug sales target pharmaceutical companies and research institutions. Real estate leasing serves commercial tenants, while hot fats and household items are sold to retail consumers. The company's segments collectively serve diverse markets across healthcare, real estate, and consumer goods. CrystalGenomics, Inc. focuses on therapeutic discovery and development, with its R&D Division driving innovation in new drug sales. The Finished Pharmaceuticals Manufacturing segment ensures steady supply of established products. Real estate leasing and household item sales provide additional revenue streams. The company's business model integrates pharmaceutical production, research, and non-pharmaceutical ventures. CG Invites Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about CG Invites Co stock

Inventory of CG Invites Co is 6.42 B KRW in 2025.

Inventory of CG Invites Co changed from 9.18 B KRW to 6.42 B KRW, representing a -30.09% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Inventory CG Invites Co since 2006 – with annual values, charts, and detailed analysis.

Inventory includes raw materials, work-in-progress, and finished goods. Efficient inventory management is crucial for profitability.

Inventory's KRW is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Inventory's CG Invites Co historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — CG Invites Co

All Key Metrics — CG Invites Co